COMP <GO>
ARQT vs ABCL // EV/EBITDA & P/E VALUATION
Arcutis Biotherapeutics Inc. (NASDAQ) VS. AbCellera Biologics Inc. (NASDAQ) • 15-METRIC TALLY: ARQT 8
— ABCL 1
■ METRIC PARITY
LAST: $32.07 (+0.31%) • MKT CAP: $4.03B
valuation
—
LAST: $12.27 (-6.19%) • MKT CAP: $3.97B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARQT VS. ABCL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARQT | ABCL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 90.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.00% | -20.50% | +17.50 | ARQT | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.16% | -4.11% | +3.95 | ARQT | /fcf-yield <GO> |
| Operating Margin | -3.30% | -60.00% | +56.70 | ARQT | /operating-margins <GO> |
| Net Profit Margin | -4.30% | -60.00% | +55.70 | ARQT | /net-margins <GO> |
| Revenue Growth (YoY) | 91.30% | 160.60% | -69.30 | ABCL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.78 | 6.60 | +1.18 | ARQT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 4/9 | +2.00 | ARQT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.0 | 49.0 | +17.00 | ARQT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.03B | $3.97B | $56.6M | ARQT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARQT REV | ABCL REV | ARQT GROSS % | ABCL GROSS % | ARQT FCF | ABCL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $376.1M | $75.1M | 90.2% | — | -$6.3M | -$174.1M |
| FY 2024 | $196.5M | $28.8M | 90.3% | — | -$112.3M | -$187.0M |
| FY 2023 | $59.6M | $38.0M | — | — | -$249.7M | -$43.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARQT // BETA 1.00
ABCL // BETA —